Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. (NQ: PHVS )

20.61 -0.06 (-0.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,845
Open 20.54
Bid (Size) 20.48 (2)
Ask (Size) 21.11 (1)
Prev. Close 20.67
Today's Range 20.12 - 21.02
52wk Range 1.770 - 26.86
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% Upside
Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ: PHVS), noting that the company stands out as one of the players with their strategy to develop and advance oral therapeutic options in both the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga

Performance

YTD
+71.32%
+71.32%
1 Month
+9.80%
+9.80%
3 Month
+28.81%
+28.81%
6 Month
+172.62%
+172.62%
1 Year
+159.28%
+159.28%

More News

Read More
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
8 Analysts Have This to Say About Pharvaris
Via Benzinga
Analyst Expectations for Pharvaris's Future
Via Benzinga
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Pharvaris To Present at the 18th German Allergy Congress
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
Why Shares of Pharvaris N.V. Are Up Tuesday
Via The Motley Fool
5 Analysts Have This to Say About Pharvaris
Via Benzinga
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
From Pharvaris N.V.
Via GlobeNewswire
Farfetch, Faraday Future Intelligent Electric, VinFast, And Other Stocks Moving Lower On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
Via Benzinga
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
From Pharvaris N.V.
Via GlobeNewswire
FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE
Via Benzinga
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces $70 Million Private Placement Financing
From Pharvaris N.V.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
From Pharvaris N.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.